Clinical Trial
doi: 10.1111/j.1532-5415.1987.tb04664.x.
A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction
- PMID: 3553281
- DOI: 10.1111/j.1532-5415.1987.tb04664.x
Item in Clipboard
Clinical Trial
A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction
J Am Geriatr Soc.
1987 May.
Abstract
In a double-blind clinical trial, vinpocetine, a synthetic ethyl ester of apovincamine, was shown to effect significant improvement in elderly patients with chronic cerebral dysfunction. Forty-two patients received 10 mg vinpocetine three times a day (tid) for 30 days, then 5 mg tid for 60 days. Matching placebo tablets were given to another 42 patients for the 90 day trial period. Patients on vinpocetine scored consistently better in all evaluations of the effectiveness of treatment including measurements on the Clinical Global Impression (CGI) scale, the Sandoz Clinical Assessment-Geriatric (SCAG) scale, and the Mini-Mental Status Questionnaire (MMSQ). There were no serious side effects related to the treatment drug.
Similar articles
-
Open-labeled phase III clinical trials with vinpocetine in Japan.Ther Hung. 1985;33(1):41-9. Ther Hung. 1985. PMID: 3915913 Clinical Trial. No abstract available.
-
[Treatment of cerebrovascular deficiencies. Therapeutic evaluation from 129 cases using the double-blind method against placebo].Sem Hop. 1984 Jan 26;60(3):169-74. Sem Hop. 1984. PMID: 6320441 Clinical Trial. French.
-
[Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions].Ideggyogy Sz. 2007 Jul 30;60(7-8):301-10. Ideggyogy Sz. 2007. PMID: 17713111 Clinical Trial. Hungarian.
-
[The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion].Orv Hetil. 2001 Feb 25;142(8):383-9. Orv Hetil. 2001. PMID: 11263076 Review. Hungarian.
-
A systematic review of vinpocetine therapy in acute ischaemic stroke.Eur J Clin Pharmacol. 1999 Jul;55(5):349-52. doi: 10.1007/s002280050639. Eur J Clin Pharmacol. 1999. PMID: 10456483
Cited by
-
Herbal medicine in the treatment of Alzheimer's disease.Am J Alzheimers Dis Other Demen. 2006 Mar-Apr;21(2):113-8. doi: 10.1177/153331750602100211. Am J Alzheimers Dis Other Demen. 2006. PMID: 16634467 Free PMC article. Review.
-
Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.J Immunol. 2015 Jun 15;194(12):5990-8. doi: 10.4049/jimmunol.1401489. Epub 2015 May 13. J Immunol. 2015. PMID: 25972475 Free PMC article.
-
Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord.PLoS One. 2015 Mar 30;10(3):e0118942. doi: 10.1371/journal.pone.0118942. eCollection 2015. PLoS One. 2015. PMID: 25822523 Free PMC article.
-
Cyclic GTP imitates the potentiating effect of the nootrope vinpocetine on the high-threshold A-current in mollusk neurons.Neurosci Behav Physiol. 1999 Nov-Dec;29(6):671-5. doi: 10.1007/BF02462482. Neurosci Behav Physiol. 1999. PMID: 10651324
-
Lack of pharmacokinetic interaction between vinpocetine and oxazepam.Br J Clin Pharmacol. 1994 Aug;38(2):143-6. doi: 10.1111/j.1365-2125.1994.tb04338.x. Br J Clin Pharmacol. 1994. PMID: 7981015 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
